Lakefront Biotherapeutics (GLPGF) Long-Term Deferred Tax (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Long-Term Deferred Tax for 14 consecutive years, with $190831.5 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax fell 87.68% year-over-year to $190831.5 in Q1 2026; TTM through Mar 2026 was $190831.5, a 87.68% decrease from a year earlier, with the FY2025 full-year figure at $220313.2, down 86.19% from the prior year.
• Long-Term Deferred Tax was $190831.5 for Q1 2026 at Lakefront Biotherapeutics, down from $226988.5 in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $4.5 million in Q1 2022 and troughed at $190831.5 in Q1 2026.
• A 5-year average of $1.4 million and a median of $1.3 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax surged 30.01% in 2024 and sank 87.68% in 2026, its largest moves.
• Over 5 years, Long-Term Deferred Tax stood at $1.4 million in 2022, then slipped by 12.88% to $1.2 million in 2023, then jumped by 30.01% to $1.6 million in 2024, then slumped by 85.59% to $226988.5 in 2025, then retreated by 15.93% to $190831.5 in 2026.
• The last three Long-Term Deferred Tax figures came in at $190831.5 (Q1 2026), $226988.5 (Q4 2025), and $979668.2 (Q3 2025), per Business Quant data.